Zenvia is a medication by Avanir Pharmaceuticals currently in development for the treatment of pseudobulbar affect. This neurological disorder is characterized by involuntary crying, uncontrollable episodes of crying and/or laughing, or other emotional displays. Zenvia contains dextromethorphan and quinidine in both 30/10 mg and 20/10 mg formulations. Quinidine is a CYP2D6 inhibitor which prevents the metabolization of DXM to DXO. This results in increased bioavailability of dextromethorphan. Zenvia will potentially be approved by the FDA as a prescription drug in the fourth calendar quarter of 2010.[1]

^ "AVANIR Pharmaceuticals Submits Complete Response to FDA Approvable Letter for Zenvia in PBA." EON 30 Apr. 2010. accessed 22 Jul 2010. http://eon.businesswire.com/portal/s...89&newsLang=en

Created by viscosity, 07-22-2010 at 05:32 PM Last edited by viscosity, 07-22-2010 at 05:33 PM 0 Comments, 270 Views